The global lung disease therapeutics market is likely to garner a market value of US$ 83,398.60 million in 2023 and is expected to accumulate a market value of US$ 152,369.26 million by registering a CAGR of 6.2% in the forecast period.
Growth of the lung disease therapeutics market can be attributed to increasing air pollution and the rising prevalence of COPD. The market for lung disease therapeutics registered a CAGR of 3.9% in the historical period 2018 to 2022.
Lungs are the complex human organ that brings in oxygen and expels carbon dioxide by expanding and relaxing continuously. Lung disease is one of the most common medical conditions globally. Lung disease is very severe and is highly responsible for increasing mortality around the globe. Lung disease leads to uneasiness and complications in respiration.
Some key lung diseases are COPD, asthma, bronchopulmonary dysplasia, and pulmonary fibrosis. Basically, there are two types of treatment for lung disease viz drug treatment and oxygen therapy. Drug treatment is most preferred by physicians as well as patients owing to its instant effect. Oxygen therapy is provided to COPD patients through ventilators and concentrators for long-term care.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The rising prevalence of COPD and asthma are the primary factors driving the market growth. The change in lifestyle of people and increase in numbers of smokers globally is likely to propel the growth of lung disease therapeutics sector. Besides, the rising geriatric population suffering from various lung diseases spur the growth of the market.
Furthermore, advancement in technology and increasing research and development leads to availability of more efficient drug therapeutics which is likely to boost the market growth.
The market is expected to show exponential growth over the forecast period. The lung disease therapeutics industry is classified on the basis of disease type, treatment type and distribution channel. By disease type, COPD segment is expected to dominate the market value of lung disease therapeutics sector.
Drug treatment is expected to be the most lucrative segment for lung disease therapeutics business by treatment type. Among all distribution channels, retail pharmacies are expected to show faster growth than other segments.
| Attributes | Details |
|---|---|
| Lung Disease Therapeutics Market CAGR (2023 to 2033) | 6.2% |
| Lung Disease Therapeutics Market Size (2023) | US$ 83,398.60 million |
| Lung Disease Therapeutics Market Size (2033) | US$ 152,369.26 million |
The Cost Associated with the Treatment of Lung Diseases Impede the Growth of the Market
Although the lung disease therapeutics market has numerous end-uses, there are numerous obstacles that likely pose a challenge to market growth. The high cost of drugs for the treatment of lung disease is likely to restrain the growth of this market to some extent.
Some side effects after consumption of anti-inflammatory drugs also hinder the growth of the lung disease therapeutics sector. All these factors are expected to derail the progress of the market.
Principal Consultant
| Countries | Market share (2022) |
|---|---|
| United States | 32.2% |
| Germany | 5.9% |
| Japan | 3.7% |
North America is expected to have the maximum market share of the lung disease therapeutics market due to the high number of people suffering from COPD and asthma in the United States After North America. In addition, technologically advanced healthcare facilities are contributing to the growth of the market.
Moreover, increasing awareness regarding early therapeutics for lung disease is contributing to the growth of the market. Thus, North America possessed 35.3% market share in 2022.
In addition, with the advent of new treatment therapies such as targeted drug therapy, stereotactic are aiding the growth of the market. According to the American Lung Association, COPD is the third most common cause of death in the country.
Rising healthcare infrastructure and favorable medical insurance are responsible for the high growth of the market in Western Europe. Rising pollution and climate change in the European region lead to robust market growth.
Moreover, government initiatives to spread awareness regarding regular lung check-ups is escalating the demand for lung disease therapeutics. Thus, Europe held a 28.7% market share in 2022. The region's market is being driven by an increase in the prevalence of chronic disease and Asthma is the most common issue among children.
A number of technological advancements in respiratory diagnostic testing have paved the way for the market's expansion, including the use of artificial intelligence and the Internet of things (IoT), among other things.
| Countries | Details |
|---|---|
| China | 9.2% |
| India | 7.5% |
The Asia Pacific is expected to remain at the forefront by generating the leading lung diseases therapeutics market share in the upcoming years. The presence of numerous leading companies in the region is anticipated to drive the regional market. The rising aging population prone to lung diseases across developing countries, such as India and China is likely to propel the demand for lung disease therapeutics in the Asia Pacific.
The high penetration rate of state-of-the-art devices and the presence of a well-established healthcare system across the Asia Pacific are a couple of other factors that foster the market. For instance, In August 2022- Sanofi and Innovent Biologics announced a collaboration to bring innovative medicines to patients in China with difficult-to-treat cancers.
Innovent is a leading biopharmaceutical company with strong clinical development capabilities and a broad commercial footprint in China.
Key start-up players in lung disease therapeutics are Omnispirant, Atriva Therapeutics, Altavant Sciences, Exvastat and ReAlta Life Sciences.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Examples of some of the market participants in the lung disease therapeutics sector identified across the value chain include GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca, Novartis, Sanofi, Roche, Teva Pharmaceuticals, Astellas Pharma, Asmacure Ltée, Dr. Reddy’s Laboratories Ltd.
Attributed to the presence of such a high number of participants, the market is highly competitive. While global players such as GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca, Novartis, and Sanofi account for considerable market size, several regional-level players are also operating across key growth regions, particularly in the Asia Pacific.
The global market size is to reach US$ 152,369.26 million by 2033.
North America is projected to emerge as a lucrative market.
The growth potential of the global market is 6.2% in 2023.
The rising numerous obstacles is likely to limit market growth.
China is likely to secure a significant CAGR of 9.2% in 2023.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Disease Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Disease Type, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Disease Type, 2023 to 2033 5.3.1. COPD 5.3.2. Chronic Bronchitis 5.3.3. Emphysema 5.3.4. Bronchopulmonary Dysplasia 5.3.5. Pulmonary Fibrosis 5.3.6. Asthma 5.3.7. Other Lung Disease Therapeutics 5.4. Y-o-Y Growth Trend Analysis By Disease Type, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Disease Type, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment Type 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Treatment Type, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment Type, 2023 to 2033 6.3.1. Drugs 6.3.1.1. Diuretics 6.3.1.2. Steroids 6.3.2. Bronchodilators 6.3.3. Antibiotics 6.3.4. Anti-inflammatory Agents 6.3.5. Oxygen Therapy 6.3.6. Other Treatment Types 6.4. Y-o-Y Growth Trend Analysis By Treatment Type, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Treatment Type, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033 7.3.1. Hospital Pharmacies 7.3.2. Retail Pharmacies 7.3.3. Online Pharmacies and E-commerce 7.3.4. Drugstores 7.3.5. Other Distribution Channels 7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022 7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 8.3.1. North America 8.3.2. Latin America 8.3.3. Western Europe 8.3.4. Eastern Europe 8.3.5. South Asia and Pacific 8.3.6. East Asia 8.3.7. Middle East and Africa 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. USA 9.2.1.2. Canada 9.2.2. By Disease Type 9.2.3. By Treatment Type 9.2.4. By Distribution Channel 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Disease Type 9.3.3. By Treatment Type 9.3.4. By Distribution Channel 9.4. Key Takeaways 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Disease Type 10.2.3. By Treatment Type 10.2.4. By Distribution Channel 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Disease Type 10.3.3. By Treatment Type 10.3.4. By Distribution Channel 10.4. Key Takeaways 11. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. UK 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Rest of Western Europe 11.2.2. By Disease Type 11.2.3. By Treatment Type 11.2.4. By Distribution Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Disease Type 11.3.3. By Treatment Type 11.3.4. By Distribution Channel 11.4. Key Takeaways 12. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. Poland 12.2.1.2. Russia 12.2.1.3. Czech Republic 12.2.1.4. Romania 12.2.1.5. Rest of Eastern Europe 12.2.2. By Disease Type 12.2.3. By Treatment Type 12.2.4. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Disease Type 12.3.3. By Treatment Type 12.3.4. By Distribution Channel 12.4. Key Takeaways 13. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. India 13.2.1.2. Bangladesh 13.2.1.3. Australia 13.2.1.4. New Zealand 13.2.1.5. Rest of South Asia and Pacific 13.2.2. By Disease Type 13.2.3. By Treatment Type 13.2.4. By Distribution Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Disease Type 13.3.3. By Treatment Type 13.3.4. By Distribution Channel 13.4. Key Takeaways 14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. China 14.2.1.2. Japan 14.2.1.3. South Korea 14.2.2. By Disease Type 14.2.3. By Treatment Type 14.2.4. By Distribution Channel 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Disease Type 14.3.3. By Treatment Type 14.3.4. By Distribution Channel 14.4. Key Takeaways 15. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. GCC Countries 15.2.1.2. South Africa 15.2.1.3. Israel 15.2.1.4. Rest of MEA 15.2.2. By Disease Type 15.2.3. By Treatment Type 15.2.4. By Distribution Channel 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Disease Type 15.3.3. By Treatment Type 15.3.4. By Distribution Channel 15.4. Key Takeaways 16. Key Countries Market Analysis 16.1. USA 16.1.1. Pricing Analysis 16.1.2. Market Share Analysis, 2022 16.1.2.1. By Disease Type 16.1.2.2. By Treatment Type 16.1.2.3. By Distribution Channel 16.2. Canada 16.2.1. Pricing Analysis 16.2.2. Market Share Analysis, 2022 16.2.2.1. By Disease Type 16.2.2.2. By Treatment Type 16.2.2.3. By Distribution Channel 16.3. Brazil 16.3.1. Pricing Analysis 16.3.2. Market Share Analysis, 2022 16.3.2.1. By Disease Type 16.3.2.2. By Treatment Type 16.3.2.3. By Distribution Channel 16.4. Mexico 16.4.1. Pricing Analysis 16.4.2. Market Share Analysis, 2022 16.4.2.1. By Disease Type 16.4.2.2. By Treatment Type 16.4.2.3. By Distribution Channel 16.5. Germany 16.5.1. Pricing Analysis 16.5.2. Market Share Analysis, 2022 16.5.2.1. By Disease Type 16.5.2.2. By Treatment Type 16.5.2.3. By Distribution Channel 16.6. UK 16.6.1. Pricing Analysis 16.6.2. Market Share Analysis, 2022 16.6.2.1. By Disease Type 16.6.2.2. By Treatment Type 16.6.2.3. By Distribution Channel 16.7. France 16.7.1. Pricing Analysis 16.7.2. Market Share Analysis, 2022 16.7.2.1. By Disease Type 16.7.2.2. By Treatment Type 16.7.2.3. By Distribution Channel 16.8. Spain 16.8.1. Pricing Analysis 16.8.2. Market Share Analysis, 2022 16.8.2.1. By Disease Type 16.8.2.2. By Treatment Type 16.8.2.3. By Distribution Channel 16.9. Italy 16.9.1. Pricing Analysis 16.9.2. Market Share Analysis, 2022 16.9.2.1. By Disease Type 16.9.2.2. By Treatment Type 16.9.2.3. By Distribution Channel 16.10. Poland 16.10.1. Pricing Analysis 16.10.2. Market Share Analysis, 2022 16.10.2.1. By Disease Type 16.10.2.2. By Treatment Type 16.10.2.3. By Distribution Channel 16.11. Russia 16.11.1. Pricing Analysis 16.11.2. Market Share Analysis, 2022 16.11.2.1. By Disease Type 16.11.2.2. By Treatment Type 16.11.2.3. By Distribution Channel 16.12. Czech Republic 16.12.1. Pricing Analysis 16.12.2. Market Share Analysis, 2022 16.12.2.1. By Disease Type 16.12.2.2. By Treatment Type 16.12.2.3. By Distribution Channel 16.13. Romania 16.13.1. Pricing Analysis 16.13.2. Market Share Analysis, 2022 16.13.2.1. By Disease Type 16.13.2.2. By Treatment Type 16.13.2.3. By Distribution Channel 16.14. India 16.14.1. Pricing Analysis 16.14.2. Market Share Analysis, 2022 16.14.2.1. By Disease Type 16.14.2.2. By Treatment Type 16.14.2.3. By Distribution Channel 16.15. Bangladesh 16.15.1. Pricing Analysis 16.15.2. Market Share Analysis, 2022 16.15.2.1. By Disease Type 16.15.2.2. By Treatment Type 16.15.2.3. By Distribution Channel 16.16. Australia 16.16.1. Pricing Analysis 16.16.2. Market Share Analysis, 2022 16.16.2.1. By Disease Type 16.16.2.2. By Treatment Type 16.16.2.3. By Distribution Channel 16.17. New Zealand 16.17.1. Pricing Analysis 16.17.2. Market Share Analysis, 2022 16.17.2.1. By Disease Type 16.17.2.2. By Treatment Type 16.17.2.3. By Distribution Channel 16.18. China 16.18.1. Pricing Analysis 16.18.2. Market Share Analysis, 2022 16.18.2.1. By Disease Type 16.18.2.2. By Treatment Type 16.18.2.3. By Distribution Channel 16.19. Japan 16.19.1. Pricing Analysis 16.19.2. Market Share Analysis, 2022 16.19.2.1. By Disease Type 16.19.2.2. By Treatment Type 16.19.2.3. By Distribution Channel 16.20. South Korea 16.20.1. Pricing Analysis 16.20.2. Market Share Analysis, 2022 16.20.2.1. By Disease Type 16.20.2.2. By Treatment Type 16.20.2.3. By Distribution Channel 16.21. GCC Countries 16.21.1. Pricing Analysis 16.21.2. Market Share Analysis, 2022 16.21.2.1. By Disease Type 16.21.2.2. By Treatment Type 16.21.2.3. By Distribution Channel 16.22. South Africa 16.22.1. Pricing Analysis 16.22.2. Market Share Analysis, 2022 16.22.2.1. By Disease Type 16.22.2.2. By Treatment Type 16.22.2.3. By Distribution Channel 16.23. Israel 16.23.1. Pricing Analysis 16.23.2. Market Share Analysis, 2022 16.23.2.1. By Disease Type 16.23.2.2. By Treatment Type 16.23.2.3. By Distribution Channel 17. Market Structure Analysis 17.1. Competition Dashboard 17.2. Competition Benchmarking 17.3. Market Share Analysis of Top Players 17.3.1. By Regional 17.3.2. By Disease Type 17.3.3. By Treatment Type 17.3.4. By Distribution Channel 18. Competition Analysis 18.1. Competition Deep Dive 18.1.1. GlaxoSmithKline 18.1.1.1. Overview 18.1.1.2. Product Portfolio 18.1.1.3. Profitability by Market Segments 18.1.1.4. Sales Footprint 18.1.1.5. Strategy Overview 18.1.1.5.1. Marketing Strategy 18.1.2. Boehringer Ingelheim 18.1.2.1. Overview 18.1.2.2. Product Portfolio 18.1.2.3. Profitability by Market Segments 18.1.2.4. Sales Footprint 18.1.2.5. Strategy Overview 18.1.2.5.1. Marketing Strategy 18.1.3. AstraZeneca 18.1.3.1. Overview 18.1.3.2. Product Portfolio 18.1.3.3. Profitability by Market Segments 18.1.3.4. Sales Footprint 18.1.3.5. Strategy Overview 18.1.3.5.1. Marketing Strategy 18.1.4. Novartis 18.1.4.1. Overview 18.1.4.2. Product Portfolio 18.1.4.3. Profitability by Market Segments 18.1.4.4. Sales Footprint 18.1.4.5. Strategy Overview 18.1.4.5.1. Marketing Strategy 18.1.5. Sanofi 18.1.5.1. Overview 18.1.5.2. Product Portfolio 18.1.5.3. Profitability by Market Segments 18.1.5.4. Sales Footprint 18.1.5.5. Strategy Overview 18.1.5.5.1. Marketing Strategy 18.1.6. Roche 18.1.6.1. Overview 18.1.6.2. Product Portfolio 18.1.6.3. Profitability by Market Segments 18.1.6.4. Sales Footprint 18.1.6.5. Strategy Overview 18.1.6.5.1. Marketing Strategy 18.1.7. Teva Pharmaceuticals 18.1.7.1. Overview 18.1.7.2. Product Portfolio 18.1.7.3. Profitability by Market Segments 18.1.7.4. Sales Footprint 18.1.7.5. Strategy Overview 18.1.7.5.1. Marketing Strategy 18.1.8. Astellas Pharma 18.1.8.1. Overview 18.1.8.2. Product Portfolio 18.1.8.3. Profitability by Market Segments 18.1.8.4. Sales Footprint 18.1.8.5. Strategy Overview 18.1.8.5.1. Marketing Strategy 18.1.9. Asmacure Ltée 18.1.9.1. Overview 18.1.9.2. Product Portfolio 18.1.9.3. Profitability by Market Segments 18.1.9.4. Sales Footprint 18.1.9.5. Strategy Overview 18.1.9.5.1. Marketing Strategy 18.1.10. Dr. Reddy’s Laboratories Ltd. 18.1.10.1. Overview 18.1.10.2. Product Portfolio 18.1.10.3. Profitability by Market Segments 18.1.10.4. Sales Footprint 18.1.10.5. Strategy Overview 18.1.10.5.1. Marketing Strategy 19. Assumptions & Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports
Lung Disease Therapeutics Market
